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Abstract 
Cytokine-induced killer (CIK) cells are a heterogeneous subset of ex-vivo expanded T 
lymphocytes  which  present  a  mixed  T-NK  phenotype  and  are  endowed  with  a 
MHC-unrestricted antitumor activity. The main functional properties of CIK cells may 
address some of the main limitations that are currently preventing the successful clinical 
translation  of  adoptive  immunotherapy  strategies.  Clinically  adequate  quantities  of 
immune effectors, sufficient for multiple adoptive infusions, may be obtained based on 
their relatively easy and inexpensive ex-vivo expansion starting from peripheral blood 
mononuclear cells. The MHC-unrestricted tumor-killing is mainly based on the interac-
tion between NKG2D molecules on CIK cells and MIC A/B or ULBPs molecules on tu-
mor cells; it has been proved effective against several solid and hematological malignan-
cies and does not require any HLA-restriction increasing the number of patients that 
might potentially benefit from such approach. Finally, CIK cells present a reduced allo-
reactivity across HLA-barriers with important clinical implications for their potential use 
as alternative to conventional Donor Lymphocyte Infusions after allogeneic hemopoietic 
cell transplant with a reduced risk of GVHD. In the present report we review the main 
functional characteristics of CIK cells discussing recent findings and future perspectives 
to improve their antitumor activity and potential clinical applications. 
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Introduction 
Adoptive immunotherapy holds great promises 
in the  scenario of potential new approaches for the 
treatment of solid tumors refractory to conventional 
therapies.  Crucial  issues  for  all  adoptive  immuno-
therapy strategies include the obtainment of sufficient 
numbers of immune effectors, recognition  of tumor 
targets  and  possible  restriction  to  specific 
HLA-haplotypes. Cytokine-Induced Killer (CIK) cells 
are  a  heterogeneous  subset  of  ex-vivo  expanded  T 
lymphocytes  whose  biological  features  make  them 
appealing  for  adoptive  immunotherapy,  addressing 
some limitations associated with other strategies tar-
geting specific Tumor-associated antigens (TAA).The 
main functional properties that favorably characterize 
CIK cells are: 1) Ex-vivo expansion 2) Reduced allo-
reactivity; 3) MHC-unrestricted tumor-killing. 
Ex-vivo expansion and phenotype of CIK 
cells 
An  important  limitation  preventing  the  suc-
cessful clinical translation of several adoptive immu-
notherapy  strategies  is  the  obtainment  of  sufficient 
numbers  of  anti-tumor  immune  effectors  and  their 
in-vivo persistence after infusion into the patients. An 
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important positive characteristic of CIK cells is their 
easy, and relatively inexpensive, ex-vivo expansion [1, 
2].  CIK  cell  precursors  are  CD3+  T  lymphocytes, 
mainly  with  a  naïve,  CD4CD8  double  negative 
(CD4-CD8-)  phenotype  [3].  They  can  be  classically 
expanded  starting  from  peripheral  blood  mononu-
clear cells (PBMC) but may also be generated from 
bone marrow or umbilical cord blood precursors [3, 
4]. The standard culture conditions require three to 
four weeks with the timed addition of IFN-γ, Ab-anti 
CD3 and IL2 [3]. IFN-γ is only added on day 0, its 
main activity is to activate the monocytes, present in 
the  initial  bulk  culture,  which  provide  both  con-
tact-dependent  (CD58/LFA-3)  and  soluble  (IL12) 
crucial signals that favor the acquisition of a final Th1 
phenotype and cytotoxic power of CIK cells [5-7]. The 
Ab  anti-CD3  provides  mitogenic  signals  to  T  lym-
phocytes  subsequently  sustained  by  IL2  that  drives 
the expansion [8, 9]. Some groups have reported the 
addition of IL7 as beneficial to increase the cytotoxic 
potential of CIK cells [10]. After 3-4 weeks of culture 
the expansion rate is reported to be variable from few 
to more than 1000 fold [2, 11-13]. Such levels of ex-
pansion,  also  considering  the  availability  of  CD3+ 
starting precursors, are extremely favorable for sub-
sequent  clinical  applications.  The  reason  of  the  re-
ported variability in the range of expansion rates  is 
not clear, additional experimental strategies are cur-
rently under investigation to further ameliorate such 
numbers, especially for those patients who may be in 
the  lower  range  (“poor  expanders”)  and  may  less 
benefit from such approach. Alternative strategies are 
based on additional soluble factors added to culture 
conditions (Thymoglobulin, IL1, IL7) [14] [10], addi-
tion of transient allogeneic stimulation or depletion of 
T regulatory cells during the expansion culture [15]. 
Our group recently reported that a transient alloge-
neic  stimulation  with  allogeneic  irradiated  PBMC 
may provide an important additional expansion boost 
to CIK cells without affecting their antitumor activity 
of safety profile [16]. Standard CIKs’ culture condi-
tions  have  been  successfully  validated  under  Good 
Manufacturers  Practice  (GMP)  conditions  [4]  and 
have allowed recent applications into clinical trials. At 
the  end  of  the  expansion  there  is  a  heterogeneous 
population of CD3+ T lymphocytes, with two main 
subsets, respectively positive (CD3+CD56+) and neg-
ative (CD3+CD56-) for the simultaneous expression of 
CD56 membrane molecule. The CD3+CD56+ fraction 
is  considered  the  main  responsible  for  the 
MHC-unrestricted antitumor activity [3, 13]. Mature 
CIK cells are mainly CD8+ but CD4+CD8- cells can 
also be present in the bulk culture, less frequent are 
subsets with a double positive (CD4+CD8+) or double 
negative (CD4-CD8-) phenotype. The terminally dif-
ferentiated  late  effector  phenotype  (CD45RO+; 
CD27low;  CD28low;  CD62L-;  CCR7-)  is  the  more 
represented among CD3+CD56+ CIK cells while the 
CD3+CD56-  counterpart  exhibits  more  earlier 
memory characteristics [17].  
Alloreactivity of CIK Cells 
A second clinically relevant property of CIK cells 
is  their  reduced  alloreactive  potential  across  MHC 
barriers that may result in a reduced risk for GVHD if 
adoptively infused after allogeneic Hemopoietic Cell 
Transplant  (HCT)  [13].  Early  preclinical  data,  ob-
tained  from  murine  models  of  HCT,  demonstrated 
that  the  adoptive  infusion  of  allogeneic  CIK  cells 
across MHC-barriers was associated with a lower risk 
of acute GVHD compared to conventional T cells . The 
main biological explanation for this beneficial effect is 
likely linked to the abundant production of IFN-γ, by 
expanded CIK cells, and its known protective action 
against GVHD [18, 19]. Compared to conventional T 
lymphocytes, allogeneic CIK cells displayed a signif-
icant lower acquisition of homing molecules, required 
for  the  entry  of  inflamed  and  GVHD  target  organs 
(α4β7,  CCR9,  E-selectin,  CXCR3  and  CCR5)  and  a 
higher susceptibility to apoptosis [20].  
Even  if  murine  studies  confirmed  a  reduced 
GVHD potential, initial clinical trials infusing donor 
CIK cells after HLA identical HCT, reported a 36% of 
GVHD incidence [21]. These events were of low grade 
but sufficient however to raise concerns about a re-
sidual alloreactivity of CIK cells that might become 
clinically  relevant  when  challenged  across  major 
HLA-barriers. Preclinical studies confirmed that hu-
man  CIK  cells  retain  a  behavior  similar  to  conven-
tional T lymphocytes, being able of intense prolifera-
tion  if  stimulated  across  major  HLA-barriers.  Such 
alloreactive-driven  proliferation  is  however  mainly 
restricted  to  the  CD3+CD56-  subset  [13].  The  first 
important implication is that a depletion of the “allo-
reactive”  (CD3+CD56-)  CIK  fraction  from  the  ex-
panded  bulk  population  may  further  reduce  their 
alloreactive  and  consequent  GVHD  potential.  This 
approach may be of particular relevance in peculiar 
HCT  settings  with  augmented  degree  of 
HLA-mismatch  between  donor  and  recipient  (i.e. 
Haploidentical HCT) and high risk of GVHD. A se-
cond possible implication of CIKs’ residual alloreac-
tivity  is  its  exploitation  to  ameliorate  their  ex-vivo 
expansion. A little modification in the standard CIKs’ 
culture conditions, with the transient addition of al-
logeneic irradiated PBMC as stimulators, was shown 
to significantly increase the final expansion rate and 
augment the percentage of CD3+CD56+ cells without Journal of Cancer 2011, 2 
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negatively  affecting  the  antitumor  activity  or  in-
creasing their alloreactivity versus third party [16].  
In general these findings are in favor of a possi-
ble use of CIK cells as alternative Donor Lymphocyte 
Infusion  (DLI)  following  allogeneic  HCT,  with  the 
possibility  of  further  decreasing  the  GVHD  in 
high-risk settings by depleting the CD3+CD56- frac-
tion  before  the  infusion.  A  second-generation  DLI 
with CIK cells might increase the overall antitumor 
activity of HCT and improve its safety profile. Such 
positive evolution might help new experimental per-
spectives of HCT like those exploring its application 
as immunotherapy treatment for solid tumors.  
Tumor killing ability of CIK cells  
The ability to efficiently kill tumor cells is the ul-
timate  basic  ability  requested  to  immune  effectors 
candidate for adoptive immunotherapy. CIK cells are 
endowed  with  a  MHC-independent  tumor  killing 
capacity  against  both  solid  and  hematologic  malig-
nancies. The antitumor activity is mainly, even if not 
exclusively, associated with the CD3+CD56+ fraction 
and it is not due to the highest percentage of CD8+ 
cells  compared  to  the  CD3+CD56-  subset[13].  The 
exact mechanism involved in tumor recognition and 
killing is not completely known but a main role seems 
to be played by the NKG2D molecule expressed on 
the  membrane  of  CIK  cells  that  interacts  with 
MHC-unrestricted  ligands  on  tumor  cells  [22].  The 
main  targets  recognized  by  NKG2D  are  MIC  A/B 
(MHC class I related molecules) and proteins of the 
ULBP family (ULBPs 1,2 and 3) [23-25] while the final 
killing is perforin and granzyme mediated. NKG2D 
has a co-stimulatory role on conventional T lympho-
cytes, while on CIK cells it acquires a tumor-receptor 
function,  following  the  ex-vivo  activation  with  IL2 
and upregulation of the DAP10 adaptor molecule [22]. 
MIC A/B are stress-induced proteins expressed by a 
wide range of  malignant  or transformed cells, their 
expression is MHC-unrestricted and not limited to a 
specific hystotype [26]. The expression of such ligands 
may also vary within the same tumor type, according 
to  variations  in  the  biological  behavior  and  aggres-
siveness of tumor phenotype. We recently reported, in 
a breast cancer preclinical model, that acquisition of 
resistance to treatment with Trastuzumab could asso-
ciate with the increased expression of MIC A/B on 
tumor cells and consequent augmented susceptibility 
to  immune-mediated  killing  by  CIK  cells  [27].  The 
antitumor activity of CIK cells have been described in 
vitro  against  several  hematologic  and  solid  malig-
nancies  including  lung,  gastrointestinal  and  mesen-
chymal tumors [13, 28-31]. The tumor killing activity 
was confirmed in vivo with murine models of tumor 
xenograft [32-34]. CIK cells are usually infused intra-
venously in the animal, they were shown to efficiently 
infiltrate  tumor  sites  and  demonstrated  a  superior 
activity  compared  to  classic  LAK  cells  against  Non 
Hodgkin Lymphoma [2, 3, 35]. The majority of pre-
clinical data were produced using allogeneic  tumor 
cell lines as targets to demonstrate the efficacy of CIK 
cells against solid tumors. While cell lines may rep-
resent  a  useful  tool  to  generate  important  proof  of 
concepts, they may not fully account for the unique 
patient-specific  biological  and  immunogenic  charac-
teristics  of  autologous  tumor  cells.  Furthermore  re-
sults  may  be  influenced,  at  least  in  part,  by 
HLA-mismatches between CIK cells and tumor tar-
gets. It is of great importance that future experiments 
may  consider  a  design  involving  autologous  tumor 
settings, to generate reliable patient-specific data that 
could  serve  as  basis  for  subsequent  clinical  transla-
tion. In this direction first reports came by the Stan-
ford group that showed activity of CIK cells against 
primary  human  ovarian  cancer  [33]  and  our  group 
that recently reported data of intense tumor killing by 
patient-derived  CIKs  against  autologous  bone  sar-
coma cells [36]. An intriguing perspective for adop-
tive immunotherapy strategies with CIK cells is the 
emerging possibility to redirect and potentiate their 
antitumor activity with TAA bispecific antibodies [37] 
or  their  engineering  to  produce  specific  cytokines 
enhancing the cytotoxicity [38] or with tumor-receptor 
molecules [39] [40, 41].  
Clinical Studies 
The  clinical  translation  of  adoptive  immuno-
therapy with CIK cells as treatment for patients with 
solid tumors is currently the object of clinical trials 
and  their  number  has  increased  in  the  very  recent 
years.  The  first  clinical  experience  included  10  pa-
tients  with  metastatic  renal  carcinoma,  colorectal 
cancer and lymphoma. Circulating CIK cells persisted 
for up to 2 weeks after the infusion, no relevant asso-
ciated  toxicities  were  reported.  One  patient  with 
lymphoma  obtained  a  complete  response  while  six 
patients had progressive diseases and three did not 
experience any change. In this first study, CIK cells 
were  engineered  to  auto-generate  IL-2  [38].  Other 
clinical trials subsequently confirmed the safety and 
feasibility  of  this  immunotherapy  approach  along 
with  demonstration  of  initial  clinical  activity.  In  a 
phase I study reported on 12 patients with advanced 
non-Hodgkin’s  lymphoma  (NHL),  metastatic  renal 
cancer or hepatocellular carcinoma (HCC), the adop-
tive infusion of CIK cells resulted in three complete 
responses and two stabilizations  of disease. Two of 
the complete responses were observed in metastatic Journal of Cancer 2011, 2 
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renal cancer and HCC, these responding patients re-
ceived  the  simultaneous  subcutaneous  injection  of 
low dose IL-2 and IFN-α respectively [42]. The above 
mentioned are, to our knowledge, the only two trials 
with  CIK  cells  for  solid  tumors  that  have  currently 
been published in Europe or U.S. A higher number of 
clinical studies have been recently performed in Asia 
with very interesting clinical results. In the setting of 
hepatocellular  carcinoma,  adjuvant  infusions  of  au-
tologous CIK cells after surgical resection, showed a 
significant increase in disease-free survival [43, 44]; an 
interesting  observation  was  the  reduction  of  HBV 
viral  load  associated  with  CIK  treatments  [45].  The 
adoptive  infusion  of  CIK  cells  produced  interesting 
clinical  responses  in  patients  with  lung  and  gastric 
cancers with a reported positive impact on survival in 
association with chemotherapy [46-49]. A summary of 
clinical trials with CIK cells for the treatment of solid 
tumors is reported in table 1. 
Overall these studies confirmed the high safety 
of adoptive immunotherapy with CIK cells with im-
portant indications suggestive for a clinical activity; 
the heterogeneity in methods and criteria for response 
assessment make still early and difficult to draw de-
finitive  statements  concerning  tumor  response  or 
impact on survival.  Recently it has been created an 
International Registry on CIK Cells (IRCC) with the 
aim of collecting data worldwide and setting standard 
criteria to report results from clinical trial with CIK 
cells [50]. Similar initiatives are very important as they 
could help a rational development of clinical research 
in the field and provide useful tools to analyze past 
and future results. These issues are crucial in order to 
derive objective and reliable conclusions on the effi-
cacy  of  CIK  cells  as  adoptive  immunotherapy  for 
cancer.  
 
Conclusions 
CIK cells represent a promising tool in the sce-
nario  of  cancer  adoptive  immunotherapy  strategies. 
Their easy and inexpensive ex-vivo expansion, along 
with the MHC-unrestricted tumor killing ability may 
overcome some crucial problems that have limited the 
diffusion  and  clinical  translation  of  other  immuno-
therapy approaches. The reduced alloreactivity across 
major  HLA-barriers  may  open  new  perspective  ap-
plications of CIK cells as alternative to conventional 
DLI after HCT, helping the extension of HCT to other 
experimental settings like the treatment of solid tu-
mors.
 
 
 
Table 1. Clinical trials of adoptive immunotherapy with CIK cells as treatment for solid tumors. 
Disease   Patients   Type of CIKs   Toxicity   Clinical Responses   Ref.  
Colorectal and renal carci-
noma; NHL  
10   Autologous   Fever: 3   CR (1) SD (3)   [38] 
NHL; Renal Carcinoma.; 
HCC  
12   Autologous   Fever: 2   CR(3); SD (2)   [42] 
Advanced NSCLC   59 (randomized)   Autologous  
(+ Chemotherapy)  
None relevant   Improved PFS and OS   [46] 
Resected HCC  
(adjuvant setting)  
127 (randomized)   Autologous   Fever: 5   Improved DFS   [43]  
HCC (adjuvant setting)   85 (randomized)   Autologous   None relevant   Reduced recurrence rate  [44]  
Gastric cancer (Stage IV)   57 (randomized)   Autologous  
(+ chemotherapy)  
None Relevant   Reduced Tumor Markers; Improved 
QOL  
[47]  
HCC   13   Autologous   Transient Fever 
(most of pts)  
Reduced tumor volume (3); Im-
proved symptoms; Decreased 
HBV-DNA load  
[45] 
Various (NLSLC; gastroin-
testinal) 
40 (randomized)  Allogeneic  
(CB-derived) 
None Relevant  Improved PFS and OS  [49] 
Gastric Cancer  156 (randomized)  Autologous (+ 
Chemotherapy)  
None Relevant  Improved Survival  [48] 
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